SES/AXESS
28.7.2022 08:52:12 CEST | Business Wire | Press release
SES and AXESS Networks (AXESS), a leading provider of satellite connectivity solutions, are accelerating digital transition of the mining industry with SES’s second-generation medium earth orbit (MEO) system O3b mPOWER , the two companies announced today. Under this multi-year, multi-million agreement, the mining sector users will be able to benefit from the cutting-edge low-latency Onshore Energy & Mining mPOWERED connectivity service.
SES’s Onshore Energy & Mining mPOWERED service will provide the highest throughput available from a satellite system and deliver dedicated and carrier-grade networks to AXESS’ customers reliably regardless of their remote locations. O3b mPOWER can deliver up to multiple gigabits per second per site, enabling AXESS’ customers to accelerate the digitalisation of their operations and sites globally, boosting profitability through access to new applications and efficiency, as well as improving staff safety and welfare. SES’s second-generation MEO connectivity service also brings the Cloud closer to the end customers and can enable edge computing to support the use of 5G and IoT in the mining industry.
Simon GattySaunt, Vice President of Networks Sales, Europe, at SES, said, “Transition towards smart mining is already turbocharging profits, and revolutionising industry’s environmental and societal impact. We are proud of the success our partnership with AXESS has already had in facilitating this change, thanks to our multi-orbit GEO and MEO network, and are excited to further accelerate it with the O3b mPOWER service.”
Guido Neumann, President AXESS EMEA said, “This agreement builds on a long and successful relationship with SES, which has helped us to provide our customers with the best-in-class, reliable and resilient connectivity for their operations. As we are seeing a considerable uptake in demand for the carrier-grade solutions globally, but especially in the EMEA and APAC region, we are honoured to play an active role in scaling the digital transition in the mining sector through introducing O3b mPOWER and the Onshore Energy & Mining mPOWERED service.”
Follow us on:
Twitter
| Facebook
| YouTube
| LinkedIn
| Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About AXESS Networks
AXESS Networks (AXESS) is a global leader in satellite-based solutions that manages the entire satellite communications value chain with engineering solutions tailored to its customers’ requirements. AXESS was founded in 2019 via the merger of CETel and Axesat, two well-established companies in Europe and Latin America. AXESS operates and owns Teleports in Germany, Colombia, Mexico, Peru, Saudi Arabia and the United Arab Emirates (UAE). It provides turnkey solutions for the individual requirements of its clients from a broad range of industries: Corporate, Energy, Maritime, Telcos, Government, Humanitarian Services and Media. More than 200 AXESS employees serve over 800 clients in 50 countries with deep market understanding. AXESS was awarded as the Independent Teleport Operator of the Year by the WTA (World Teleport Association) in 2021. Further information is available at: www.axessnet.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006150/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom